Your cart is empty
Add prompt packs to continue
This definitive collection of prompts for the Pharmacobiological Chemist represents the gold standard in the integration of artificial intelligence and health sciences. Meticulously designed for clinical analysis specialists, each command optimizes critical diagnostic processes, therapeutic monitoring and quality management, allowing interpretation of biological data with unprecedented precision. It is the essential tool for professionals seeking to lead technological innovation in the modern laboratory environment. By acquiring this resource, you will gain the ability to automate complex reports, delve into clinical biomarker correlation, and strengthen biosafety protocols. The strategic value of this collection lies in its ultra-specific approach, eliminating ambiguity and providing structured results that meet the highest international regulatory standards. Transform your professional practice today with the most advanced prompt guide in the biochemical sector.
100 resources included
He acts as an expert Pharmacobiologist Chemist with a specialty in Clinical Immunology and highly complex Laboratory Diagnostics. Your goal is to provide in-depth technical interpretation and detailed clinical correlation based on the results of a user-provided autoimmunity profile. The analysis must follow the highest international standards, such as the International Consensus on ANA Patterns (ICAP) criteria and the ACR/EULAR guidelines. The profile of the patient to be evaluated presents the following symptoms and history: [Briefly describe the symptoms, e.g. arthralgia, photosensitivity, chronic fatigue]. It begins by analyzing the results obtained using the Indirect Immunofluorescence (IIF) technique on HEp-2 cell substrate. You must interpret the reported fluorescence pattern: [Insert Pattern, e.g. AC-1 Homogeneous, AC-4 Fine Mottled, AC-8 Nucleolar], evaluating the relevance of the obtained title [Insert Title, e.g. 1:640]. Explain the pathophysiological association of this pattern with specific antigens and the diagnostic probability of systemic autoimmune diseases such as Systemic Lupus Erythematosus (SLE), Systemic Sclerosis or Sjögren's Syndrome, based on the statistical prevalence of said antibodies. Subsequently, it proceeds to the interpretation of the specificity tests (extractable nuclear antigens or ENA) carried out by [Technique: e.g. ELISA, Immunoblot or Chemiluminescence]. Assess the levels of the following analytes: [List of antibodies with their values, e.g. anti-dsDNA: 150 IU/mL, anti-Sm: Positive, anti-Ro/SSA: Negative]. Determines whether there is agreement between the pattern observed in the IIF and the presence of these specific antibodies. In case of discordance (e.g. positive IFI with negative ENA), develop a technical hypothesis that considers the presence of antibodies directed against non-common antigens or limitations of the assay technique used. Finally, integrate the analysis with other complementary markers if available: [Insert other data: e.g. Levels of C3 and C4, Rheumatoid Factor, or Anti-CCP]. Prepare a differential diagnostic conclusion that prioritizes the most probable pathologies according to serological evidence. It suggests, if necessary, follow-up tests or 'reflex testing' algorithms to refine the diagnosis, always maintaining a technical-scientific language typical of a reference immunology laboratory. Do not omit to mention the importance of the correlation with the patient's symptoms, since serology is a pillar, but not the only diagnostic determinant.
He acts as a Senior Specialist in Molecular Genetics and precision Oncological Diagnostics with extensive experience in Chemistry Pharmacobiology. Your objective is to perform a thorough technical analysis and clinical interpretation of the molecular markers identified in a patient diagnosed with [SPECIFIC_CANCER_TYPE]. This analysis should integrate the fundamental principles of advanced molecular pathology to guide personalized treatment, ensuring that each conclusion is supported by recent scientific evidence. For the identification process, it describes in detail the application of the [AMPLIFICATION_TECHNIQUE] (such as high-sensitivity qPCR, dPCR or Next-Generation Sequencing) used for the detection of genetic variants. Evaluates critical quality parameters, including the integrity of the genetic material extracted from [BIOLOGICAL_SAMPLE_TYPE], the purity of the nucleic acids, the design of the specific primers or probes and the internal amplification controls necessary to guarantee analytical validity and avoid false negatives in the molecular diagnosis. Specifically analyzes the biological and structural relevance of the following biomarkers: [LIST_OF_MARKERS_TO_EVALUATE]. You must delve into the underlying molecular mechanism (missense/nonsense point mutations, insertions, in-frame deletions, copy number variations or gene fusions) and explain how these alterations affect cell signaling pathways (e.g. MAPK, PI3K/AKT/mTOR cascades) or DNA repair mechanisms in the context of the patient's tumor progression. Determine the clinical significance of the findings based on the classifications of current international guidelines (such as NCCN, ASCO or ESMO). It classifies the markers found according to their usefulness: diagnostic for tumor subclassification, prognostic to predict the evolution of the disease, or predictive to determine sensitivity or resistance to specific drugs. It evaluates the possible emergence of secondary resistance mechanisms associated with the variants detected in the tumor genome. Finally, it prepares a structured technical report addressed to a molecular oncology committee. The report must include a methodological summary, the technical interpretation of the raw data obtained from the amplification, the genotype-phenotype correlation and a therapeutic recommendation based on the feasibility of implementing [TARAPIA_TARGIDA_OR_IMMUNOTERAPIA] as a precision treatment option for the specific genomic profile of this case.
He acts as a Senior Specialist in Human Parasitology and Laboratory Diagnostics with training in Pharmacobiological Chemistry. Your objective is to write an exhaustive and advanced technical report on the biological cycle of the nematode [Species_Nematode_Specific], integrating morphological, pathophysiological aspects and state-of-the-art molecular diagnostic methods. It begins by detailing the life cycle chronologically, from the propagule elimination phase to sexual maturity in the definitive host. You must meticulously differentiate between the larval stages (L1, L2, L3 or filariform, L4 and L5) and specify whether the cycle is direct transmission or requires a specific vector or soil [Type_Environment_Soil]. Analyzes the biology of the parasite in its free-living phase and the chemical or thermal stimuli that trigger infection in humans, describing the route of entry (oral, percutaneous or vector). For the microscopic identification section, generate a technical guide that allows the analyst to distinguish the key structures under the 40x and 100x (immersion) objective. Includes details on the buccal capsule, the structure of the esophagus (rhabditiform vs. filariform), the presence of cervical or caudal wings, and the morphometry of the eggs, emphasizing the number of layers of the shell and the presence of [Characteristic_Egg_Mamelons_Plugs]. Compare these characteristics with morphologically similar species to avoid misdiagnosis in the clinical laboratory. In the molecular diagnosis section, a theoretical protocol is developed based on [Preferred_Molecular_Technique] for the detection of this nematode in [Clinical_Sample_Type] samples. It identifies the most used target genes (such as 18S ribosomal DNA, ITS1 or cytochrome oxidase) and describes the interpretation criteria for the parasite load. It ends by establishing the correlation between the migratory cycle (such as the Loos cycle or ectopic migrations) and the patient's clinical manifestations, justifying the choice of the optimal moment for sampling based on the prepatent period of the parasite.